These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 24385535

  • 1. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM, Garcia DA, Crowther MA.
    Blood; 2014 Feb 20; 123(8):1152-8. PubMed ID: 24385535
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [Abstract] [Full Text] [Related]

  • 3. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun 15; 22(139):155-9. PubMed ID: 23866358
    [Abstract] [Full Text] [Related]

  • 4. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM, Uhlmeyer EM, Schmidt DP, Schardt GL.
    Hosp Pract (1995); 2014 Dec 15; 42(5):108-25. PubMed ID: 25485923
    [Abstract] [Full Text] [Related]

  • 5. Bleeding and antidotes in new oral anticoagulants.
    Majeed A, Schulman S.
    Best Pract Res Clin Haematol; 2013 Jun 15; 26(2):191-202. PubMed ID: 23953907
    [Abstract] [Full Text] [Related]

  • 6. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ.
    Biomed Res Int; 2014 Jun 15; 2014():583794. PubMed ID: 25136597
    [Abstract] [Full Text] [Related]

  • 7. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A, Daw HA, Crowther MA.
    Cleve Clin J Med; 2013 Jul 15; 80(7):443-51. PubMed ID: 23821689
    [Abstract] [Full Text] [Related]

  • 8. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis.
    Arch Cardiovasc Dis; 2013 Jul 15; 106(6-7):382-93. PubMed ID: 23810130
    [Abstract] [Full Text] [Related]

  • 9. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA.
    Am J Health Syst Pharm; 2013 May 15; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract] [Full Text] [Related]

  • 10. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.
    Clin Res Cardiol; 2013 Jun 15; 102(6):399-412. PubMed ID: 23669868
    [Abstract] [Full Text] [Related]

  • 11. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 15; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 12. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM, Crowther MA.
    Eur Heart J; 2013 Feb 15; 34(7):489-498b. PubMed ID: 23220847
    [Abstract] [Full Text] [Related]

  • 13. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 15; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 14. [Extended options of anticoagulant treatment in thromboembolism].
    Karetová D, Bultas J.
    Vnitr Lek; 2014 Nov 15; 60(11):977-84. PubMed ID: 25600045
    [Abstract] [Full Text] [Related]

  • 15. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A, Michel MS.
    Urologe A; 2014 Jun 15; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH.
    Clin Lab Med; 2014 Sep 15; 34(3):443-52. PubMed ID: 25168936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.